Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Provigil indications amended in U.K.

June 12, 2006

Escitalopram, but not duloxetine, affects sexual function in patients with depression

June 12, 2006

Serotonin 5-HT6 antagonist PRX-07034 begins phase I study

June 9, 2006

Enrollment opens in phase II study of AL-208 for CABG-associated MCI

June 9, 2006

Data from trial of eszopiclone in insomniac patients with depression further analyzed

June 9, 2006

PF-670462: new potent CKIe inhibitor evokes phase delays

June 9, 2006

Progesterone may be of benefit in treating brain trauma

June 9, 2006

Betaferon approved in Europe as first-line treatment for earliest stages of MS

June 8, 2006

Abilify launched in Japan

June 8, 2006

AZ-001 studied in phase IIb trial for migraine

June 8, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...